

GLOBUS MEDICAL INC  
Form 8-K  
August 17, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) August 17, 2017**

**GLOBUS MEDICAL, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**2560 General Armistead Avenue, Audubon, PA**

**001-35621**  
**(Commission**

**File Number)**

**04-3744954**  
**(I.R.S. Employer**

**Identification No.)**

**19403**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (610) 930-1800

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

On August 17, 2017, Globus Medical, Inc. issued a press release announcing that Excelsius GPS , a revolutionary robotic guidance and navigation system, has been 510(k) cleared by the U.S. Food and Drug Administration. A copy of our press release announcing the clearance is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release, dated August 17, 2017

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 17, 2017

**GLOBUS MEDICAL, INC.**

By: /s/ **DANIEL T. SCAVILLA**  
Name: Daniel T. Scavilla  
Title: Senior Vice President and Chief  
Financial Officer

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Press Release, dated August 17, 2017